MedTrace Logo

Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01280786 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2014-02-03

No results posted yet for this study

Summary

This is a phase 1 study to test the safety of escalating doses of elesclomol sodium given to patients with advanced myeloid leukemia.

Conditions

Interventions

DRUG

Elesclomol Sodium

Weekly intravenous administration of escalating doses of elesclomol sodium provided response is seen after the first 4 week cycle.

Sponsors & Collaborators

  • Synta Pharmaceuticals Corp.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2014-06-30
Completion
2014-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01280786 on ClinicalTrials.gov